Shan Feng

Shan Feng

Auto-generated profile, based on publicly available information

Shan Feng

Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital, 2650 Hvidovre, Denmark

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 May 2015 in Immunology
Verified
Journal Article
Closed access
PDF file
SFShan Feng
Shan Feng
SMSuzi H. Madsen
Suzi H. Madsen
NVNatasja N. Viller
Natasja N. Viller
ANAnita V. Neutzsky‐Wulff
Anita V. Neutzsky‐Wulff
GGGeisler Geisler
Geisler Geisler
KSKalle Söderström
Kalle Söderström

1 February 2017 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
Jun LiangJun Liang
Jun Liang
LZLin Zhang
Lin Zhang
XTXiang‐Long Tan
Xiang‐Long Tan
YQYun-Kun Qi
Yun-Kun Qi
SFShan Feng
Shan Feng
CTChang‐Lin Tian
Chang‐Lin Tian

18 January 2022 in Viruses
Verified
Journal Article
Open access
PDF file
UFUlrik Fahnøe
Ulrik Fahnøe
LPLONG VAN PHAM
LONG VAN PHAM
CFCarlota Fernandez-Antunez
Carlota Fernandez-Antunez
RCRui Costa
Rui Costa
LRLizandro René Rivera-Rangel
Lizandro René Rivera-Rangel
JBJens Bukh
Jens Bukh
The COVID-19 pandemic continues to threaten healthcare systems worldwide due to the limited access to vaccines, suboptimal treatment options, and the continuous emergence of new and more transmissible SARS-CoV-2 variants. Reverse-genetics studies of viral genes and mutations have proven highly valuable in advancing basic virus research, leading to the development of therapeutics. We developed a functional and highly versatile full-length SARS-CoV-2 infectious system by cloning the sequence of a COVID-19 associated virus isolate (DK-AHH1) into a bacterial artificial chromosome (BAC). Viruses recovered after RNA-transfection of in vitro transcripts into Vero E6 cells showed growth kinetics and remdesivir susceptibility similar to the DK-AHH1 virus isolate. Insertion of reporter genes, green fluorescent protein, and nanoluciferase into the ORF7 genomic region led to high levels of reporter activity, which facilitated high throughput treatment experiments. We found that putative coronavirus remdesivir resistance-associated substitutions F480L and V570L—and naturally found polymorphisms A97V, P323L, and N491S, all in nsp12—did not decrease SARS-CoV-2 susceptibility to remdesivir. A nanoluciferase reporter clone with deletion of spike (S), envelope (E), and membrane (M) proteins exhibited high levels of transient replication, was inhibited by remdesivir, and therefore could function as an efficient non-infectious subgenomic replicon system. The developed SARS-CoV-2 reverse-genetics systems, including recombinants to modify infectious viruses and non-infectious subgenomic replicons with autonomous genomic RNA replication, will permit high-throughput cell culture studies—providing fundamental understanding of basic biology of this coronavirus. We have proven the utility of the systems in rapidly introducing mutations in nsp12 and studying their effect on the efficacy of remdesivir, which is used worldwide for the treatment of COVID-19. Our system provides a platform to effectively test the antiviral activity of drugs and the phenotype of SARS-CoV-2 mutants.

29 June 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
AOAnna Offersgaard
Anna Offersgaard
CHCarlos Rene Duarte Hernandez
Carlos Rene Duarte Hernandez
APAnne Finne Pihl
Anne Finne Pihl
RCRui Costa
Rui Costa
NVNandini Prabhakar Venkatesan
Nandini Prabhakar Venkatesan
JGJudith Gottwein
Judith Gottwein
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has demonstrated the value of pursuing different vaccine strategies. Vaccines based on whole viruses, a widely used vaccine technology, depend on efficient virus production. This study aimed to establish SARS-CoV-2 production in the scalable packed-bed CelCradleTM 500-AP bioreactor. CelCradleTM 500-AP bottles with 0.5 L working volume and 5.5 g BioNOC™ II carriers were seeded with 1.5 × 108 Vero (WHO) cells, approved for vaccine production, in animal component-free medium and infected at a multiplicity of infection of 0.006 at a total cell number of 2.2–2.5 × 109 cells/bottle seven days post cell seeding. Among several tested conditions, two harvests per day and a virus production temperature of 33 °C resulted in the highest virus yield with a peak SARS-CoV-2 infectivity titer of 7.3 log10 50% tissue culture infectious dose (TCID50)/mL at 72 h post-infection. Six harvests had titers of ≥6.5 log10 TCID50/mL, and a total of 10.5 log10 TCID50 were produced in ~5 L. While trypsin was reported to enhance virus spread in cell culture, addition of 0.5% recombinant trypsin after infection did not improve virus yields. Overall, we demonstrated successful animal component-free production of SARS-CoV-2 in well-characterized Vero (WHO) cells in a scalable packed-bed bioreactor.


1 March 2011 in Protein Expression and Purification
Verified
Journal Article
Closed access
WYWei Yang
Wei Yang
WXWenjuan Xia
Wenjuan Xia
JMJingjing Mao
Jingjing Mao
DXDaqi Xu
Daqi Xu
JCJianhe Chen
Jianhe Chen
JSJing Su
Jing Su